Literature DB >> 19372732

Heterozygous inhibition in prion infection: the stone fence model.

Atsushi Kobayashi1, Masaki Hizume, Kenta Teruya, Shirou Mohri, Tetsuyuki Kitamoto.   

Abstract

The human PrP gene (PRNP) has two major polymorphic codons: 129 for methionine (M) or valine (V) and 219 for glutamate (E) or lysine (K). The PRNP heterozygotes appear to be protected from sporadic CJD compared to the PRNP homozygotes. The molecular mechanism responsible for these protective effects of PRNP heterozygosity has remained elusive. In this review, we describe the inhibition of PrP conversion observed in a series of transmission studies using PRNP heterozygous animal models. In vCJD infection, the conversion incompetent human PrP 129V molecules showed an inhibitory effect on the conversion of human PrP 129M molecules in the 129M/V heterozygous mice. Furthermore, though the human PrP 219E and PrP 219K were both conversion competent in vCJD infection, these conversion competent PrP molecules showed an inhibitory effect in the 219E/K heterozygous animals. To explain this heterozygous inhibition, we propose a possible mechanism designated as the stone fence model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372732      PMCID: PMC2676740          DOI: 10.4161/pri.3.1.8514

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  35 in total

1.  Evidence for assembly of prions with left-handed beta-helices into trimers.

Authors:  Cédric Govaerts; Holger Wille; Stanley B Prusiner; Fred E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-21       Impact factor: 11.205

2.  From conversion to aggregation: protofibril formation of the prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

3.  Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.

Authors:  Carole Crozet; Yea-Lih Lin; Clément Mettling; Chantal Mourton-Gilles; Pierre Corbeau; Sylvain Lehmann; Véronique Perrier
Journal:  J Cell Sci       Date:  2004-10-19       Impact factor: 5.285

4.  Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.

Authors:  Philipp Meier; Nicolas Genoud; Marco Prinz; Manuela Maissen; Thomas Rülicke; Andreas Zurbriggen; Alex J Raeber; Adriano Aguzzi
Journal:  Cell       Date:  2003-04-04       Impact factor: 41.582

5.  Pro----leu change at position 102 of prion protein is the most common but not the sole mutation related to Gerstmann-Sträussler syndrome.

Authors:  K Doh-ura; J Tateishi; H Sasaki; T Kitamoto; Y Sakaki
Journal:  Biochem Biophys Res Commun       Date:  1989-09-15       Impact factor: 3.575

6.  Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease.

Authors:  J Collinge; M S Palmer; A J Dryden
Journal:  Lancet       Date:  1991-06-15       Impact factor: 79.321

7.  Competition between different scrapie agents in mice.

Authors:  A G Dickinson; H Fraser; V M Meikle; G W Outram
Journal:  Nat New Biol       Date:  1972-06-21

8.  Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers.

Authors:  M Horiuchi; S A Priola; J Chabry; B Caughey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

9.  Prion interference is due to a reduction in strain-specific PrPSc levels.

Authors:  Jason C Bartz; Michelle L Kramer; Meghan H Sheehan; Jessica A L Hutter; Jacob I Ayers; Richard A Bessen; Anthony E Kincaid
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPSc replication in vitro.

Authors:  Hitaru Kishida; Yuji Sakasegawa; Kota Watanabe; Yoshio Yamakawa; Masahiro Nishijima; Yoshiyuki Kuroiwa; Naomi S Hachiya; Kiyotoshi Kaneko
Journal:  Amyloid       Date:  2004-03       Impact factor: 7.141

View more
  7 in total

1.  Role of the goat K222-PrP(C) polymorphic variant in prion infection resistance.

Authors:  Patricia Aguilar-Calvo; Juan Carlos Espinosa; Belén Pintado; Alfonso Gutiérrez-Adán; Elia Alamillo; Alberto Miranda; Irene Prieto; Alex Bossers; Olivier Andreoletti; Juan María Torres
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 2.  Application of yeast to studying amyloid and prion diseases.

Authors:  Yury O Chernoff; Anastasia V Grizel; Aleksandr A Rubel; Andrew A Zelinsky; Pavithra Chandramowlishwaran; Tatiana A Chernova
Journal:  Adv Genet       Date:  2020-05-04       Impact factor: 1.944

Review 3.  Human prion diseases: surgical lessons learned from iatrogenic prion transmission.

Authors:  David J Bonda; Sunil Manjila; Prachi Mehndiratta; Fahd Khan; Benjamin R Miller; Kaine Onwuzulike; Gianfranco Puoti; Mark L Cohen; Lawrence B Schonberger; Ignazio Cali
Journal:  Neurosurg Focus       Date:  2016-07       Impact factor: 4.047

4.  Effects of polymorphisms in ovine and caprine prion protein alleles on cell-free conversion.

Authors:  Martin Eiden; Elizabeth Ortega Soto; Thomas C Mettenleiter; Martin H Groschup
Journal:  Vet Res       Date:  2011-02-15       Impact factor: 3.683

5.  Deciphering the pathogenesis of sporadic Creutzfeldt-Jakob disease with codon 129 M/V and type 2 abnormal prion protein.

Authors:  Atsushi Kobayashi; Yasushi Iwasaki; Hiroyuki Otsuka; Masahito Yamada; Mari Yoshida; Yuichi Matsuura; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  Acta Neuropathol Commun       Date:  2013-11-13       Impact factor: 7.801

6.  Protective V127 prion variant prevents prion disease by interrupting the formation of dimer and fibril from molecular dynamics simulations.

Authors:  Shuangyan Zhou; Danfeng Shi; Xuewei Liu; Huanxiang Liu; Xiaojun Yao
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

7.  Allelic Interference in Prion Replication Is Modulated by the Convertibility of the Interfering PrPC and Other Host-Specific Factors.

Authors:  Juan Carlos Espinosa; Olivier Andreoletti; Alba Marín-Moreno; Severine Lugan; Patricia Aguilar-Calvo; Hervé Cassard; Patricia Lorenzo; Jean-Yves Douet; Ana Villa-Díaz; Naima Aron; Irene Prieto; Alvina Huor; Juan María Torres
Journal:  mBio       Date:  2021-03-16       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.